GRPR and breast cancer: In vitro analysis of the DTX-PLGA-BBN cytotoxicity in GRPR-positive breast cancer cells (MDA-MB-231) indicated a significant improvement in efficacy over the free drug, Taxotere, and DTX-PLGA, with IC50 values being, respectively, 35.53 ng/mL for the targeted nanocarriers, 142.24 ng/ml for the non-targeted DTX-loaded NPs, and more than 375 ng/ml for DTX and Taxotere®.